Nasdaq · Biotech stocks database
XERS — Xeris Biopharma Holdings Inc.
XERS (Xeris Biopharma Holdings Inc.) stock: $8.86, $1.62B market cap, $121.8M cash, $1.68B EV, $1.93B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Assets
Pipeline
Trials
Holders
Enterprise value
$1,682.5M
Balance sheet
Cash $121.8M Debt $188.8M Net cash -$67.1M Enterprise value $1,682.5M Basic shares 173.6M shares Fully diluted shares 217.6M shares Fully diluted market cap $1,927.8M Cash per share $0.70
Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history Loading XERS daily closes…
Loading price history…
Pipeline assets Recorlev
Approved · Active Modality: small molecule (cortisol synthesis inhibitor, oral)
Aliases levoketoconazole
Target 11-beta-hydroxylase (cortisol synthesis inhibition)
Indications Endogenous hypercortisolemia in adult patients with Cushing's syndrome (surgery not an option or not curative) (Approved) Status note Approved for endogenous hypercortisolemia in Cushing's syndrome. Subject to generic ANDA litigation.
Gvoke
Approved · Active Modality: peptide injection (ready-to-use liquid-stable glucagon; XeriSol formulation)
Aliases glucagon
Target glucagon receptor
Indications Severe hypoglycemia (diabetes, pediatric and adult patients age 2+) (Approved) Status note Approved ready-to-use glucagon (PFS, HypoPen, Kit) for severe hypoglycemia.
Keveyis
Approved · Active Modality: small molecule (oral)
Aliases dichlorphenamide
Target carbonic anhydrase inhibitor
Indications Primary Periodic Paralysis (PPP): hyperkalemic, hypokalemic, and related variants (Approved) Status note First US therapy approved for hyperkalemic, hypokalemic, and related PPP variants.
XP-8121
Phase 2 · Active Modality: peptide injection (once-weekly subcutaneous levothyroxine; XeriSol formulation)
Status note Phase 3-ready; working with FDA and planning to initiate a Phase 3 trial of once-weekly SC levothyroxine. No Phase 3 start date disclosed.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.